Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended June 30, 2001, for AP Pharma, Inc. (formerly Advanced Polymer Systems, Inc., name changed May 9, 2001). The company operates primarily through licensing agreements, royalty collection, and the sale of analytical standards. Following the July 2000 sale of its cosmeceutical and toiletry business to R.P. Scherer Corporation, the company has focused on pharmaceutical development, specifically the Biochronomer system, and royalty-generating partnerships.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2001 | Six Months Ended June 30, 2000 |
|---|---|---|
| Total Revenues | $1,970,952 | $1,599,287 |
| Net Loss | $(2,318,608) | $(413,385) |
| Operating Loss | $(2,835,468) | $(1,660,978) |
| Cash and Cash Equivalents (End of Period) | $4,155,903 | $2,670,810 |
| Marketable Securities | $15,882,058 | N/A (Not reported in 2000 balance sheet) |
| Total Assets | $23,922,899 | $26,996,162 (Dec 31, 2000) |
| Total Liabilities | $4,771,326 | $5,836,908 (Dec 31, 2000) |
| Working Capital | $18,005,523 | $20,087,191 (Dec 31, 2000) |
| Net Cash Used in Operating Activities | $(2,408,477) | $(694,158) |
Revenue Composition (6 Months 2001): Royalties ($1,374,400) and Product Revenues ($596,552).
Expense Composition (6 Months 2001): R&D ($2,922,202), G&A ($1,439,171), Cost of Sales ($206,639).
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 23% year-over-year, driven primarily by a 39% increase in royalties ($1.37M vs $0.99M) due to the launch of Carac(TM) for actinic keratoses.
- Increased Net Loss: Net loss widened significantly to $2.32M from $0.41M. This was driven by a 108% increase in R&D expenses ($2.92M vs $1.40M) related to pre-clinical trials for the Biochronomer system and a shift from income to loss in discontinued operations.
- Discontinued Operations: The company reported a loss of $184,000 from discontinued operations (cosmeceutical business) compared to income of $1.35M in the prior year. The 2001 loss is attributed to legal fees associated with the Kligman lawsuit.
- Interest Income: Interest income surged 423% to $623,000, resulting from interest earned on the $25 million cash proceeds received from the 2000 asset sale.
- Debt Elimination: Interest expense dropped to $0 as all outstanding debt was repaid using proceeds from the 2000 asset sale.
Outlook, Risks, and Management Commentary
- Liquidity: Management states that existing cash, marketable securities, and expected revenue streams are sufficient to meet working capital requirements for the foreseeable future.
- R&D Focus: Capital is being expended on pre-clinical trials for the bioerodible Biochronomer system for implantable and injectable drug delivery.
- Legal Contingency: The company is defending a lawsuit filed by Douglas and Albert Kligman alleging partnership rights to a product. The company denies liability, citing a binding license agreement, and expects no material adverse effect on financial statements.
- Accounting Changes: The company noted the issuance of SFAS No. 141 and 142 regarding business combinations and goodwill, which will be adopted in fiscal year 2002. Management does not expect a material effect on financial statements.
Investor Verification Checklist
- Royalty Sustainability: Verify the sales performance of Carac(TM) and the stability of the partnership with Dermik Laboratories/Aventis to ensure continued royalty growth.
- R&D Burn Rate: Monitor the timeline and cost of pre-clinical trials for the Biochronomer system, as R&D expenses are currently exceeding total revenues.
- Legal Exposure: Track the status of the Kligman lawsuit to confirm the company's assertion that damages will not be material.
- Cash Runway: Assess the rate of cash consumption against the $20M+ in liquid assets (cash and marketable securities) to determine the runway for operations without new financing.